Research progress of mesenchymal stem cells therapy for right heart failure associated with pulmonary arterial hypertension
10.3760/cma.j.cn112434-20201114-00504
- VernacularTitle:间充质干细胞治疗肺动脉高压所致右心衰竭的研究进展
- Author:
Yuhai ZHANG
1
;
Libing LI
;
Liang WANG
;
Weimin HUANG
;
Biao HOU
;
Qin LI
;
Yuanbin WU
;
Rong WANG
Author Information
1. 兴安盟人民医院乳腺甲状腺外科，乌拉浩特 137400
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2022;38(8):504-507
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension is a progressive disease characterized by pulmonary vascular remodeling and eventually develops into right heart failure, which seriously affects the quality of life and safety of patients. Traditional drug therapy can alleviate disease progression, but the prognosis is poor.Mesenchymal stem cells have been shown to be effective in experimental pulmonary hypertension and right heart failure, which is an important research direction in the future.In this paper, the research progress of mesenchymal stem cells in pulmonary hypertension and right heart failure is reviewed.
